513 related articles for article (PubMed ID: 30671741)
1. PET/CT Imaging of NSCLC with a α
Flechsig P; Lindner T; Loktev A; Roesch S; Mier W; Sauter M; Meister M; Herold-Mende C; Haberkorn U; Altmann A
Mol Imaging Biol; 2019 Oct; 21(5):973-983. PubMed ID: 30671741
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the RGD Motif-Containing α
Roesch S; Lindner T; Sauter M; Loktev A; Flechsig P; Müller M; Mier W; Warta R; Dyckhoff G; Herold-Mende C; Haberkorn U; Altmann A
J Nucl Med; 2018 Nov; 59(11):1679-1685. PubMed ID: 29674419
[TBL] [Abstract][Full Text] [Related]
3. Clinical Translation of a
Feng X; Wang Y; Lu D; Xu X; Zhou X; Zhang H; Zhang T; Zhu H; Yang Z; Wang F; Li N; Liu Z
J Nucl Med; 2020 Oct; 61(10):1461-1467. PubMed ID: 32086242
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. PET/CT imaging of head-and-neck and pancreatic cancer in humans by targeting the "Cancer Integrin" αvβ6 with Ga-68-Trivehexin.
Quigley NG; Steiger K; Hoberück S; Czech N; Zierke MA; Kossatz S; Pretze M; Richter F; Weichert W; Pox C; Kotzerke J; Notni J
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1136-1147. PubMed ID: 34559266
[TBL] [Abstract][Full Text] [Related]
6. Identification of a Novel ITGα
Altmann A; Sauter M; Roesch S; Mier W; Warta R; Debus J; Dyckhoff G; Herold-Mende C; Haberkorn U
Clin Cancer Res; 2017 Aug; 23(15):4170-4180. PubMed ID: 28468949
[No Abstract] [Full Text] [Related]
7. In Vivo PET Imaging of the Cancer Integrin αvβ6 Using
Notni J; Reich D; Maltsev OV; Kapp TG; Steiger K; Hoffmann F; Esposito I; Weichert W; Kessler H; Wester HJ
J Nucl Med; 2017 Apr; 58(4):671-677. PubMed ID: 27980050
[TBL] [Abstract][Full Text] [Related]
8. The Use of PET Imaging for Prognostic Integrin α
Huang CW; Hsieh WC; Hsu ST; Lin YW; Chung YH; Chang WC; Chiu H; Lin YH; Wu CP; Yen TC; Huang FT
Theranostics; 2017; 7(16):4013-4028. PubMed ID: 29109795
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Evaluation of
Ganguly T; Bauer N; Davis RA; Foster CC; Harris RE; Hausner SH; Roncali E; Tang SY; Sutcliffe JL
J Nucl Med; 2023 Apr; 64(4):639-644. PubMed ID: 36207137
[TBL] [Abstract][Full Text] [Related]
10.
Ren J; Zhu S; Zhang G; Tan X; Qiu L; Lin J; Jiang L
Mol Pharm; 2022 Jul; 19(7):2620-2628. PubMed ID: 35674464
[TBL] [Abstract][Full Text] [Related]
11. Dimerization of a phage-display selected peptide for imaging of αvβ6- integrin: two approaches to the multivalent effect.
Singh AN; McGuire MJ; Li S; Hao G; Kumar A; Sun X; Brown KC
Theranostics; 2014; 4(7):745-60. PubMed ID: 24883124
[TBL] [Abstract][Full Text] [Related]
12. The Effects of an Albumin Binding Moiety on the Targeting and Pharmacokinetics of an Integrin α
Hausner SH; Bauer N; Davis RA; Ganguly T; Tang SYC; Sutcliffe JL
Mol Imaging Biol; 2020 Dec; 22(6):1543-1552. PubMed ID: 32383076
[TBL] [Abstract][Full Text] [Related]
13. Comparing the Diagnostic Potential of 68Ga-Alfatide II and 18F-FDG in Differentiating Between Non-Small Cell Lung Cancer and Tuberculosis.
Kang F; Wang S; Tian F; Zhao M; Zhang M; Wang Z; Li G; Liu C; Yang W; Li X; Wang J
J Nucl Med; 2016 May; 57(5):672-7. PubMed ID: 26719378
[TBL] [Abstract][Full Text] [Related]
14. 18F-fluorobenzoate-labeled cystine knot peptides for PET imaging of integrin αvβ6.
Hackel BJ; Kimura RH; Miao Z; Liu H; Sathirachinda A; Cheng Z; Chin FT; Gambhir SS
J Nucl Med; 2013 Jul; 54(7):1101-5. PubMed ID: 23670900
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of [ 68 Ga]Ga-Pentixafor versus [ 18 F]FDG PET/CTs in non-small cell lung cancer: a head-to-head comparative study.
Mirshahvalad SA; Manafi-Farid R; Fallahi B; Seifi S; Geramifar P; Emami-Ardekani A; Eftekhari M; Beiki D
Nucl Med Commun; 2023 Sep; 44(9):803-809. PubMed ID: 37334548
[TBL] [Abstract][Full Text] [Related]
16. Validation of In-House Kit-Like Synthesis of
Thakral P; Das SS; Dhiman S; Manda D; Virupakshappa CB; Malik D; Sen I
Cancer Biother Radiopharm; 2023 Sep; 38(7):468-474. PubMed ID: 37093129
[No Abstract] [Full Text] [Related]
17. Dual-time point 18F-FDG PET/CT scan for differentiation between 18F-FDG-avid non-small cell lung cancer and benign lesions.
Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
Ann Nucl Med; 2009 Jul; 23(5):427-35. PubMed ID: 19437097
[TBL] [Abstract][Full Text] [Related]
18. Inter-heterogeneity and intra-heterogeneity of α
Kang F; Wang Z; Li G; Wang S; Liu D; Zhang M; Zhao M; Yang W; Wang J
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1520-1528. PubMed ID: 28405726
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of peptide-based radiotracers for integrin αvβ6-positive pancreatic carcinoma.
Müller M; Altmann A; Sauter M; Lindner T; Jäger D; Rathke H; Herold-Mende C; Marmé F; Babich J; Mier W; Haberkorn U
Nuklearmedizin; 2019 Aug; 58(4):309-318. PubMed ID: 31075798
[TBL] [Abstract][Full Text] [Related]
20. Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients.
Kramer GM; Frings V; Hoetjes N; Hoekstra OS; Smit EF; de Langen AJ; Boellaard R
J Nucl Med; 2016 Sep; 57(9):1343-9. PubMed ID: 27103020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
